Loading...
Loading...
BCYC| Name | Value |
|---|---|
| Revenues | 19.5M |
| Cost of Revenue | 1.7M |
| Gross Profit | 17.9M |
| Operating Expense | 65.3M |
| Operating I/L | -47.4M |
| Other Income/Expense | 4.8M |
| Interest Income | 5.6M |
| Pretax | -42.2M |
| Income Tax Expense | -15.7M |
| Net Income/Loss | -26.5M |
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company specializing in developing a novel class of medicines for diseases with unmet medical needs. The company's lead product candidate, BT1718, is a bicycle toxin conjugate (BTC) currently in Phase I/IIa clinical trials targeting tumors expressing Membrane Type 1 matrix metalloprotease. Additionally, the company has a pipeline of oncology product candidates, including BT5528 and BT8009, in various stages of clinical trials. Bicycle Therapeutics also engages in collaborations with biopharmaceutical companies and organizations to develop programs in therapeutic areas such as anti-infective, cardiovascular, ophthalmology, and respiratory indications.
